Increased Healthcare Utilization in Hidradenitis Suppurativa and Arthritis: A Propensity Score-Matched Analysis from a Hospital-Based Cohort

Introduction: Hidradenitis suppurativa (HS) has been linked to arthritis, but large real-world analyses remain limited. This study evaluated the prevalence, risk, and clinical impact of arthritis in patients with HS, focusing on healthcare use. Methods: A retrospective multicenter cohort was assembl...

Full description

Bibliographic Details
Authors: Garbayo-Salmons, P, Rodrigo-Parés, A, Saus, E, Moreno, M, Carreras, A, Feliu-Hernàndez, C, Exposito-Serrano, V, Ribera, M, Sabat, M, Calvet, J
Format: article
Status:Published version
Publication Date:2026
Country:España
Institution:Institut d'Investigació i Innovació Parc Taulí (I3PT)
Repository:r-I3PT. Repositorio Institucional Producción Científica del Institut d'Investigació i Innovació Parc Taulí
OAI Identifier:oai:dnet:r-i3pt______::75159bb333b7ee0d4a0054de420f757c
Online Access:https://i3pt.portalinvestigacion.com/publicaciones/7184
Access Level:Open access
Keyword:Hidradenitis suppurativa
Arthritis
Spondyloarthritis
Immune-mediated diseases
TriNetX
Description
Summary:Introduction: Hidradenitis suppurativa (HS) has been linked to arthritis, but large real-world analyses remain limited. This study evaluated the prevalence, risk, and clinical impact of arthritis in patients with HS, focusing on healthcare use. Methods: A retrospective multicenter cohort was assembled using the TriNetX network. Adults with HS (n = 226,047) were compared with matched controls without HS (n = 12,286,573). Arthritis prevalence, 5-year risk, and healthcare utilization were assessed after 1:1 propensity score matching. Results: Arthritis prevalence was higher in the HS group (6.22% vs. 5.66%). Over 5 years, HS patients had a higher risk of arthritis than the general hospital population (2.22% vs. 1.73%; risk ratio 1.29, 95% CI: 1.23-1.34). Within the HS cohort, those with arthritis showed greater use of systemic therapies, including tumor necrosis factor inhibitors (27% vs. 6%) and interleukin inhibitors (12% vs. 2%). They also had more outpatient visits, emergency visits, and hospitalizations across 1-, 3-, and 5-year periods. Conclusions: Findings should be interpreted considering the limitations of administrative datasets, including potential misclassification and underreporting. Overall, HS is associated with a higher 5-year risk (cumulative incidence) of arthritis, and patients with both conditions exhibit substantially increased healthcare use.